English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 3 March 2025, 15:41 JST
Share:
    

Source: Eisai
"Fatigue Recovery While You Sleep!" Eisai to Launch Designated Quasi-Drug Drink "Chocola BB Nightwell"
- Easy-To-Drink Grapefruit Flavor Containing Herbal Medicines and Glycine -

TOKYO, Mar 3, 2025 - (JCN Newswire) - Eisai Co., Ltd. announced today the launch of the new nutritional drink “Chocola BB® Nightwell” (designated quasi-drug product), a nutritional drink to help recovery from the accumulated fatigue of the day during sleep, on Monday, March 3. The productbelongs to the Chocola BB brand, which supports people’s beauty and health, and will be available at pharmacy and drugstores throughout Japan.

Chocola BB Nightwell contains eight active ingredients, including vitamin B2, which supports fatmetabolism and converts it into energy, and glycine, which improves sleep quality associated with poornutrition, as well as herbal medicines (Crataegus oxyacantha and Citrus unshiu peel). With a grapefruit flavor, Chocola BB Nightwell is easy to drink, low in calories (5.1 kcal per bottle), and caffeine-free, allowing consumption before bedtime. By promoting fatigue recovery during sleep, Chocola BB Nightwell supports a refreshed start to the day.

Since the launch of Chocola BB tablets in 1952, the Chocola BB brand has been offering products forover 70 years to address various skin and fatigue symptoms, in line with the needs of each era. The current Chocola BB drink lineup consists of designated quasi-drugs for fatigue care, including “ChocolaBB® Light” for daily fatigue, “Chocola BB® Royal 2” for severe fatigue, and “Chocola BB® Hyper” for low vitality.

By marketing the Chocola BB series of products, Eisai is committed to addressing the diverse needswithin fatigue care, and supporting the beauty and wellness of even more people.

Please refer to the product’s website for details about Chocola BB Nightwell (Japanese only) www.eisai.jp/products/chocola/chocola_bb_nightwell

FOr more information, visit https://www.eisai.com/news/2025/news202514.html

Media Inquiries:
Public Relations Department, Eisai Co., Ltd.
+81-(0)3-3817-5120



Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
2026年5月18日 14時50分 JST
エーザイ、「SX 銘柄 2026」に初選定
2026年5月8日 17時00分 JST
エーザイとバイオジェン・インク、抗 Aβ抗体レカネマブの皮下注射製剤「LEQEMBI(R) IQLIK(TM)」の早期アルツハイマー病に対する初期療法に関する米国 FDA による優先審査の状況について
2026年4月22日 10時40分 JST
エーザイとMerck & Co., Inc、進行腎細胞がん(RCC)患者様を対象とした一次治療としての併用療法を評価する臨床第III相「LITESPARK-012」試験の状況について
Tuesday, 21 April 2026, 20:52 JST
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Friday, 27 March 2026, 20:14 JST
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
More news >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575